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Available online 16 August 2016Objectives: Anti-Müllerian hormone (AMH)measurement is useful as an aid in the evaluation of ovarian re-
serve. In the past, its conventional use was restricted by the low-throughput and variability of existing manual
AMH assays. We developed the automated Access AMH assay for the quantitative determination of AMH levels
on the Access family of immunoassay systems. The analytical performance of this new assay was evaluated.
Design andmethods: Sensitivity, dilution linearity, assay imprecision, AMH sample stability, lot-to-lot com-
parison and correlation with AMH Gen II assay (Beckman Coulter, Inc.) were evaluated. Reference intervals for
Access AMH were established in healthy females, males, newborns (≤60 days) and pediatric males classiﬁed
by Tanner stages.
Results: The limit of blank and limit of detectionwere below0.0077 and 0.0098 ng/mL, respectively. The limit
of quantitation was 0.010 ng/mL. The total imprecision ranged from 2.4 to 5.2%. Linearity was observed up to
24 ng/mL. Sample storage at room temperature up to 48 h, at 2–8 °C up to 7 days and at−20 °C up to 15months
had no impact on measured AMH. The correlation study gave a coefﬁcient between 0.99 and 1 and a regression
slope between 0.89 and 0.92. Excellent lot-to-lot comparability was observed on controls and patient samples
with a maximum bias of 3.7% between 2.81 and 15.03 ng/mL.
Conclusions: The fully automated Access AMH immunoassay demonstrates excellent analytical
performance. As a consequence, the availability of this assay will represent a robust, fast and precise alternative
to manual AMH assay testing.
© 2016 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Lot-to-lot variability1. Introduction
Anti-Müllerian hormone (AMH) is a member of the transforming
growth factor-β family. AMH is a glycoprotein, which circulates as a
dimer composed of two identical 72 kDa monomers that are linked by
disulﬁde bridges [1,2].
In males, AMH is secreted by Sertoli cells of the testes. AMH concen-
trations are high until puberty, and then decline slowly to residual levels
after puberty [3]. This decrease of AMH production during puberty is
associated with the pubertal development phase. The most signiﬁcant
reduction in AMH concentrations occurs between Tanner stages II andirdjian), sbord@beckman.com
beckman.com (R. Masica),
.com (L. Nicouleau),
n.com (P.-Y. Marquet).
ty of Clinical Chemists. PublishedIII, and is concurrent with the increase of testosterone concentrations
within the testes [4].
In females, AMH expression has been observed in the fetus at ap-
proximately 36 weeks in granulosa cells of preantral ovarian follicles
and is produced by these cells until menopause [5,6].
The measurement of AMH can be used in fertility investigations to
help predict a women's response to ovarian stimulation, estimate of
time tomenopause and also to diagnose andmonitorwomenwith poly-
cystic ovary syndrome (PCOS) [7–9]. SerumAMH levels are two to three
times higher in PCOS comparedwith levels in womenwith normal ova-
ries and the level of AMH also correlates with the severity of PCOS [9].
Circulating levels of AMH serve as a reliable indicator of testicular func-
tion and descent, and also helps for neonatal gender determination [10].
With the increasing clinical importance of AMH, rapid development
of several AMH assays has occurred [11]. The AMH Gen II assay
(Beckman Coulter, Inc.) is one of the ﬁrst manual AMH enzyme-linked
immunosorbent assays (ELISA) which are still commonly used in clini-
cal laboratory practice. [12–14].by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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intensive and their results are highly inﬂuenced by handling practices.
Therefore, an automated AMH assay, providing more reproducible and
accurate results, is needed [15].
In order to meet these challenges, Beckman Coulter developed a
fully automated assay for AMH on the Access family of immunoassay
systems (Access AMH, Beckman Coulter, Inc.) using the same pair of an-
tibodies used in the AMH Gen II assay [16].
There are three publications on the Access AMH assay that have re-
ported an analytical performance assessment carried out using a 10-day
protocol [17,18] or intra-assay precision only [19].
We report here on the technical performance assessment of the Ac-
cess AMH assay including an evaluation of sensitivity, linearity, repeat-
ability over a 20-day period, intermediate imprecision, and total
imprecision on the Access 2 and UniCel DxI 800 systems. Furthermore,
we evaluated short-term sample stability and long-term frozen storage
stability of AMH samples at−20 °C and−70 °C for up to 15months and
lot-to-lot comparability using 9 lots of reagents.
Moreover, we determined AMH reference interval values for healthy
adult females, adult males, newborns (≤60 days) and pediatric males
classiﬁed by Tanner stages.
2. Material and methods
2.1. Assay principle
The Access AMH assay is a simultaneous one-step sandwich chemi-
luminescence immunoassay using two mouse monoclonal antibodies
recognizing total AMH [16,20]. Twenty microliters of a sample are
added to themousemonoclonal antibody F2B/7A conjugated to alkaline
phosphatase, and paramagnetic particles coated with themousemono-
clonal antibody F2B/12H. After incubation and ﬁnal wash, the test tubes
are developed by adding a chemiluminescent substrate to produce a vis-
ible signal, which indicates the concentration of AMH in the sample de-
termined by means of a stored, six-point calibration curve. Total assay
time is approximately 40min. Calibrators are prepared with human re-
combinant total AMH (140 kDa) produced in Chinese hamster ovary
(CHO) epithelial cells which were transfected with a Simian Virus 40
(SV40) immortalizing gene along with the gene coding for human
AMH [21].
2.2. Standardization
No international standard recognized in agreement with the Inter-
national Federation of Clinical Chemistry is currently available. The Ac-
cess AMH assay was harmonized with the AMH Gen II assay revised
version (Beckman Coulter, Inc.) using 239 frozen samples covering the
range of the assay (0–24 ng/mL) stored at −80 °C (n = 159) and
−20 °C (n = 75) (Golden West Biologicals, Temecula, CA, USA and
Hospital Saint Joseph, Marseille, France). The AMH Gen II ELISA kit
procedure was revised in July 2013 with the addition of a premix step
to eliminate the complement interference in fresh samples [22]. Mean
of AMH concentrations obtained using two microplate lots and two
calibrator lots for the Gen II assay were assigned to each of the 239 sam-
ples. These AMH concentrations were then transferred to Access AMH
mean signal counts to assign values to reference calibrators prepared
with recombinant total AMH (Immunotech (IOT), Marseille, France) in
HEPES buffer using three reagent pack lots.
2.3. Samples
Written informed consent was obtained from all participants, which
was approved by an Institutional Review Board of each participating fa-
cility. The Access AMH performances were evaluated using routine
serum or lithium heparin plasma samples. The method comparison ex-
periment was carried out using unused routine serum samples whichwere aliquoted and stored at−80 °C. The origin of the samples is men-
tioned for each performance paragraph.
2.4. Imprecision
The imprecision study was performed according to the Clinical and
Laboratory Standards Institute (CLSI) EP5-A2 guideline [23] using four
pooled plasma samples (Trina Bioreactives, Zurich, Switzerland) at
AMH concentrations ranging from 0.10 to 16.9 ng/mL. Samples were
randomized and measured in duplicate with two runs per day for a
total of 20 days on three reagent lots, three DxI 800 and three Access
2 instruments. The standard deviation (SD) and coefﬁcient of variation
(%CV) were calculated for repeatability (within-run precision), inter-
mediate imprecision (between-run precision) and total imprecision
(within-lab precision).
2.5. Sensitivity
The Access AMH assay sensitivity was determined according to the
CLSI guideline EP17-A2 [24].
For the limit of blank (LoB) determination, four 0-level analyte sam-
ples (calibrator S0 of four calibrator lots) were run over three days with
four runs per day and ﬁve replicates per run on two Access 2 and two
DxI 800 instruments using two reagent pack lots. The 95th percentile
of the upper reference limit was calculated from a total of 120 replicates
per sample and per reagent lot for Access 2 and DxI 800 instruments.
The LoB corresponds to the highest apparent amount of AMH expected
when replicates of a sample containing no AMH are measured.
The limit of detection (LoD) was determined using ﬁve low-level
serum samples (Trina Bioreactives, Zurich, Switzerland) above the LoB
with nine replicates per day over ﬁve days on two Access 2 and two
DxI 800 instruments using one reagent pack and calibrator lot. The
LoD corresponds to the lowest AMH concentration whose distribution
of results shows 95% of the results above the LoB. Ninety-ﬁve percent
represents the probability of detecting the AMH when it is present.
The limit of quantitation (LoQ) was determined over ﬁve days using
seven low-level AMH serum samples (Trina Bioreactives, Zurich,
Switzerland), two Access 2 and two DxI 800 instruments, two reagent
pack lots with nine replicates per sample. The LoQ corresponds to the
lowest AMH amount that can be accurately quantiﬁed with a 20% CV.
2.6. Linearity
Linearity of the reportable range was evaluated according to CLSI
guideline EP06-A [25]. The studywas completed on twoAccess 2 instru-
ments using two reagent lots. One high serum sample (N24 ng/mL) and
one low serum sample (b0.02 ng/mL) were used as neat and mixed
samples to make seven evenly distributed sample concentrations. Mea-
sured AMH values were plotted against the expected AMH concentra-
tions and linearity was determined using the polynomial regression
method.
2.7. Method comparison
A comparison of the Access AMH assay and the AMH Gen II ELISA
assay (Beckman Coulter, Inc.) was performed on 104 serum samples
(internal blood draw and Hospital Saint Joseph, Marseille, France)
across the range of the assay (0.15–22.5 ng/mL) using two reagents
lots onAccess 2 andDxI 800 instruments. Result analysiswasperformed
using Passing-Bablok regression, Bland-Altman plot and Spearman
correlation.
2.8. Sample stability
Serum with gel, serum no gel (without gel) and lithium heparin
plasma samples from 11 anonymized blood donors (Beckman Coulter
1269G. Demirdjian et al. / Clinical Biochemistry 49 (2016) 1267–1273employees, MN, USA) were collected, aliquoted and stored at different
temperatures for different time periods. Room temperature stored
samples were analyzed in triplicate on one Access 2 instrument at ﬁve
different time points; immediately (day 0), after 8 h, 16 h, 24 h and
48 h. 2–8 °C stored samples were analyzed after 7 days and the frozen
samples (−20 °C) after 30 days and 60 days. The average percent differ-
ence from the baseline was calculated.
Four serum gel tubes from ﬁve anonymized blood donors (Beckman
Coulter employees, MN, USA) ranging from 5.89 to 22.19 ng/mL were
collected but not centrifuged and stored up to 6 days at room tempera-
ture. Centrifugation was performed on one tube of each donor prior
testing after 0, 1, 2 and 6 days. The percent difference from the baseline
was calculated for each donor at each time point.
For assessment of the long term sample stability; samples from 10
anonymized blood donors (Beckman Coulter employees, MN, USA)
were collectedwith serumgel, serumnogel and lithiumheparin plasma
tubes. Samples ranging from 0.61 to 12.15 ng/mL were aliquoted and
ﬁve were stored at −20 °C, the other ﬁve were stored at −70 °C.
Aliquots were tested in triplicate after 60, 120, 240, 360, 390 and
452 days on one Access 2 instrument using one reagent and calibrator
lot. The percent difference from the baseline over time was calculated
for each sample and the mean percent difference of the 5 patient
samples per storage condition (−20 °C and −70 °C) was plotted
using linear regression with 95% conﬁdence intervals (CI).
Comparison plots were used to evaluate between the three sample
types. The slopes and 95% CI were calculated.
2.9. Reference interval
AMH reference intervals in healthy individuals were obtained from
864 serum samples (Cerba Specimen Services, Cergy Pontoise, France;
Northwest Biological Inc., Bellevue, USA; BioreclamationIVT, New
York, USA and Etablissement Francais du Sang Rhone Alpes, Lyon,
France) which were run in duplicate on one Access 2 instrument with
two reagent pack lots and one calibrator lot. Subjects with known
endocrine or metabolic disorders, infertility, autoimmune and cancer
diseases, infectious disease, diagnosed endometriosis, gonadal dysfunc-
tion were excluded. Results on 83 adult males, 483 adult females, 55
male newborns and 44 female newborns were analyzed using robust
method applied to Box\\Cox transformed data, according to recom-
mendation in: Horn and Pesce (2005) [26]. One hundred ninety nine
healthy pediatric males, aged between 8 and 19, were included to ana-
lyze the pediatric male reference range classiﬁed by Tanner stages.
Healthy pediatric male donors were included in the protocol and classi-
ﬁed using the Tanner scale of physical development based on external
primary and secondary sex characteristics.
2.10. Lot-to-lot comparison
Four lots of two levels of assay controls and two lots of three levels of
patient samples were run in duplicate on nine reagent pack lots using
12 calibrator lots over a year. Percent differences of doses obtained on
each replicate were calculated versus their assigned values (target).
The target for the controls level 1 and level 2 are respectively 4.6 and
14.1 ng/mL (lot 1); 4.6 and 14.1 ng/mL (lot 2); 5.07 and 15.03 ng/mL
(lot 3); 4.92 and 14.9 ng/mL (lot 4). The target for the patient samples
level 1, level 2, and level 3 are 2.81, 6.03, and 13.1 (lot 1) and 4.15,
5.71, and 13.9 (lot 2), respectively. The average of the percent differ-
ences from the target was also calculated per reagent pack lot.
2.11. Statistical analysis
The analysis of regression (Bland-Altman and Passing-Bablok
methods) was performed using Analys-it software Version 3.5. All
other statistical analyses were performed using JMP software
Version 10.3. Results
3.1. Imprecision
Repeatability, intermediate and total imprecision of Access AMH
assay are similar between DxI 800 and Access 2 instruments. The
total imprecision for AMH plasma pools between concentrations of
0.10–16.9 ng/mL ranged from 2.4 to 5.2% CV. Results of imprecision
study are summarized in Table 1.
3.2. Sensitivity
The LoB and LoD ranged from 0.0024 ng/mL to 0.0077 ng/mL and
from 0.0049 ng/mL to 0.0098 ng/mL, respectively for Access 2 and DxI
800 instruments. The LoQ was 0.01 ng/mL for Access 2 and DxI 800
instruments.
3.3. Linearity
Fig. 1 shows the results of linearity for the Access 2 instrument. The
linearity study was conducted based on CLSI EP06-A using polynomial
regression method. The Access AMH assay presented excellent linearity
in the measuring range (0.15–22.5 ng/mL) with a maximum deviation
of 2.45% for samples N0.16 ng/mL and b0.0037 ng/mL for samples
≤0.16 ng/mL (Fig. 1).
3.4. Method comparison
The Access AMH assay and themanual AMHGen II assay displayed a
strong correlation (Spearman rank correlation coefﬁcient at 0.99 for Ac-
cess 2 andDxI 800 instruments). The Passing-Bablok regression analysis
resulted in slope values ranged from 0.89 to 0.92 on both instruments
using two lots of reagent packs. The AccessAMHmeasurements showed
up to 11% lower sample concentrations as compared to the AMH Gen II
assay over the entire measuring range (0.15–22.5 ng/mL). Correlation
data for Access 2 system on one reagent lot is shown in Fig. 2. A mean
bias of 1.3% was observed for the Access AMH on Access 2 and a mean
bias of 0.8% was observed for the Access AMH on DxI 800 based on
the Bland-Altman difference plots (see Supplementary data Fig. A2).
These biases indicated good agreement across the measuring range be-
tween the AMH Gen II assay and the Access AMH assay on both
instruments.
3.5. Sample stability
The AMH sample stability showed a variation b5.5% between day 0
and 48 h at room temperature, 7 days at 2–8 °C or 60 days frozen stored
at−20 °C for the three different tube types (serum gel/no gel and lith-
ium heparin plasma) (data not shown, see Supplementary data
Table A.1). For the AMH whole blood stability study, the variation be-
tween day 0 and day 6 days at room temperature on the serum gel
tubeswas b5% (see Supplementary data Fig. A.2). For long term stability
at−20 °C or−70 °C, no signiﬁcant trend (p N 0.061)was observed over
15 months and themean % difference between day 0 and 452 days was
below 10% for the three different tube types (serum gel/no gel and lith-
ium heparin plasma) (Table 2).
3.6. Reference interval
The median AMH values for the newborn (b60 days of age) were
46.94 ng/mL and 0.16 ng/mL, respectively for males and females. For
the normal healthy males (N18 years old), the AMH median value is
4.87 ng/mL. The median AMH values for females decreased with age
from 3.71 ng/mL to 0.29 ng/mL for 18 years old to 41–45 years old, re-
spectively. After 46 years of age, the median AMH value for females
was 0.01 ng/mL. For the different Tanner stages for males, which
Table 1
Repeatability, intermediate and total imprecision of Access AMH assay. Standard deviation (SD) and coefﬁcient of variation (CV%)were calculated based onmeasurements of each plasma
pool on three reagent lots, three DxI 800 and three Access 2 instruments according to CLSI EP-5A2 guideline.
Instrument Sample Grand mean
(n= 80)
(ng/mL)
Repeatability Intermediate imprecision Total imprecision
SD
(ng/mL) %CV
SD
(ng/mL) %CV
SD
(ng/mL) %CV
Access 2 (1) Sample 1 0.12 0.002 1.7 0.003 2.7 0.004 3.2
Sample 2 2.49 0.039 1.5 0.067 2.7 0.077 3.1
Sample 3 6.01 0.089 1.5 0.153 2.5 0.177 2.9
Sample 4 16.9 0.254 1.5 0.413 2.4 0.485 2.9
Access 2 (2) Sample 1 0.10 0.002 2.1 0.004 4.2 0.005 4.7
Sample 2 2.42 0.034 1.4 0.061 2.5 0.070 2.9
Sample 3 5.89 0.074 1.2 0.135 2.3 0.154 2.6
Sample 4 16.4 0.208 1.3 0.381 2.3 0.434 2.6
Access 2 (3) Sample 1 0.11 0.002 2.2 0.003 2.5 0.004 3.3
Sample 2 2.50 0.036 1.4 0.059 2.3 0.069 2.8
Sample 3 6.0 0.092 1.5 0.109 1.8 0.143 2.4
Sample 4 16.4 0.240 1.5 0.380 2.3 0.449 2.7
DxI 800 (1) Sample 1 0.11 0.003 2.7 0.003 3.2 0.005 4.2
Sample 2 2.48 0.054 2.2 0.079 3.2 0.096 3.9
Sample 3 6.07 0.146 2.4 0.208 3.4 0.254 4.2
Sample 4 16.6 0.451 2.7 0.493 3.0 0.668 4.0
DxI 800 (2) Sample 1 0.10 0.003 3.4 0.004 3.9 0.005 5.2
Sample 2 2.47 0.090 3.7 0.057 2.3 0.107 4.3
Sample 3 6.09 0.147 2.4 0.137 2.2 0.201 3.3
Sample 4 16.7 0.524 3.1 0.540 3.2 0.752 4.5
DxI 800 (3) Sample 1 0.11 0.002 2.3 0.003 2.4 0.004 3.3
Sample 2 2.46 0.067 2.7 0.067 2.7 0.095 3.9
Sample 3 5.9 0.129 2.2 0.063 1.1 0.143 2.4
Sample 4 15.9 0.327 2.1 0.324 2.0 0.461 2.9
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adolescents and young adults, the median AMH values decreased
most signiﬁcantly from Tanner stage 1 to 3 with a median value de-
crease of 56.58 to 8.64 ng/mL. The reference interval results are
displayed in the Table 3.
3.7. Lot-to-lot comparison
Lot-to-lot comparability on four different Access AMH quality con-
trol material lots showed a percent difference from the target valueFig. 1. Linearity experiment for theAccess AMHassay according to CLSI EP06-A guidelines.
A high serum sample (N24 ng/mL) and a low serum sample (b0.02 ng/mL) were analyzed
in addition to 7 evenly distributed dilutions which were created by mixing the high and
low sample. All diluted samples were measured in replicates of four. Measured AMH
concentrations were plotted against the expected AMH concentrations. All results are
calculated in ng/mL. Polynomial Fit Degree = 2 equation: AMH Observed value =
0.0002 + 0.956 ∗ AMH Target value + 0.0019 ∗ (AMH Target value − 0.0037)2.
Polynomial Fit Degree = 3 equation: AMH Observed value = 0.0001 + 0.9598∗AMH
Target value + 0.0011 ∗ (AMH Target value − 0.0037)2 + 2.7476e-5 ∗ (AMH Target
value− 0.0037)3. The graph shows an example of the result obtained on one Access 2
using one reagent lot.ranging from −4.1% to 4.3% per replicate of each control level and
−6.2% to 5.6% for the two patient sample lots see Fig. 3. In average,
per pack lot, the percent differences ranged from 0.13% to 2.25% for
the four assay control lots with the two different concentration levels
and from−3.7% to 2.5% for the two patient sample lots with the three
different concentration levels using multiple calibrator lots over a year
of testing.Fig. 2. Method comparison between the Access AMH assay and the AMH Gen II assay
analyzed via Passing-Bablok regression. AMH values were measured for 104 serum
samples across the range of the assay (0.15–22.5 ng/mL). The graph shows an example
of the result obtained on one Access 2 instrument using one reagent lot. The line of
identity is given as the dashed line, the Passing-Bablok regression line y = 0.12 + 0.91x
as the solid line, the Spearman's correlation coefﬁcient r being 0.99.
Table 2
Effect of long term stability (over 15 months) on 10 matched serum gel, no gel, lithium heparin plasma samples ranging from 0.61 to 12.15 ng/mL at two different storage temperatures
(−20 °C and−70 °C).
Storage condition Sample type Slope (% Difference per month) Std error of slope p-Value
−20 °C Plasma gel tube −0.23 0.15 0.146
Serum gel tube −0.25 0.21 0.252
Serum no gel −0.18 0.13 0.171
−70 °C Plasma gel tube −0.31 0.17 0.077
Serum gel tube −0.39 0.20 0.061
Serum no gel −0.25 0.13 0.061
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An analytical performance evaluationwas conducted on a novel, au-
tomated AMH assay for the Access family of immunoassay systems. The
results clearly demonstrate that the Access AMH assay is superior to
currentmanual AMH assays [12]. As such, its remarkable analytical per-
formance makes it suitable for implementation in routine practice. An
LoQ of 0.01 ng/mL showed signiﬁcantly higher sensitivity compared to
manual AMH ELISA assays and also to the automated Elecsys AMH
assay (Roche Diagnostics GmbH) [27,28]. All evaluated sensitivity pa-
rameters conﬁrmed the excellent analytical sensitivity of the Access
AMH assay and aligned with a recent publication of Pearson et al.
reporting the LoB and LoD values to be lower than those designated in
the Instruction for Use from Beckman Coulter [18].
Three previous studies on the Access AMH assay have shown good
repeatability and intermediate imprecision assessed on a 10-day maxi-
mum experiment without calculation of total imprecision [17–19].
In accordancewith these reports,we conﬁrmed that the Access AMH
assay exhibited low CVs and high reproducibility on both Access 2 and
DxI 800 systems (CV ≤ 3.7% for repeatability, CV ≤ 4.2% for intermediate
and CV ≤ 5.2% for total imprecision) based on a 20-day experiment. Fur-
thermore, the Access AMH assay showed excellent linearity in the assay
measuring range (0.15–22.5 ng/mL) using the polynomial regression
method in accordance with CLSI EP06-A. Therefore, the Access AMH
assay exhibited good analytical performance fulﬁlling the accuracy re-
quirements for a fully automated assay.
Some recent studies revealed discrepancies of reported within-
subject and between-method variability suggesting that AMH may be
prone to pre-analytical instability [29]. We showed highly stable AMH
values under room temperature, refrigerated and frozen conditions on
the three different sample tube types. Furthermore, long-term storage
of samples at−20 °C and−70 °C for up to 15months had no signiﬁcant
impact on measured AMH. In addition, this is the ﬁrst paper to report
the AMHwhole blood stability study showing that for up to a 6-day pe-
riod, unseparated serum gel tubes can easily be stored at roomTable 3
Access AMH reference range for male and female adults, pediatric samples and male Tanner st
Reference group Age range (years) N Median
ng/mL (pmol/L)
95% reference interva
ng/mL
(95% CI)
Adult males N18 83 4.87 (34.77) 0.73–16.05 (0.36–1.4
Adult females 18–25 80 3.71 (26.49) 0.96–13.34 (0.72–1.3
Adult females 26–30 82 2.27 (16.21) 0.17–7.37 (0.08–0.34
Adult females 31–35 80 1.88 (13.43) 0.07–7.35 (0.02–0.27
Adult females 36–40 80 1.62 (11.60) 0.03–7.15 (0.00–0.11
Adult females 41–45 79 0.29 (2.05) 0.00–3.27 (0.00–0.00
Adult females ≥46 82 0.01 (0.06) 0.00–1.15 (0.00–0.00
Male Tanner stage 1 8–13 39 56.58 (403.97) 4.95–144.48 (NA⁎ an
Male Tanner stage 2 8–17 40 26.55 (189.58) 5.02–140.06 (NA⁎ an
Male Tanner stage 3 10–19 40 8.64 (61.70) 2.61–75.90 (2.18–3.3
Male Tanner stage 4 12–18 40 7.15 (51.02) 0.43–20.14 (0.014–2
Male Tanner stage 5 11–19 40 7.00 (49.96) 1.95–21.20 (1.17–3.2
Newborn males 0 (≤60 days) 55 46.94 (335.17) 15.11–266.59 (11.42
Newborn females 0 (≤60 days) 44 0.16 (1.17) 0.01–3.39 (0.00–0.02
⁎ Lower limit with robust method was out of the range of observed data.temperature or couriered to a remote site assay service without the
need for centrifugation and refrigeration.
In method comparison studies of Access AMH assay and AMH Gen II
assay therewas a high correlationwith r N 0.99 for samples covering the
relevant concentration range of ovarian reserve assessment. This corre-
lation study demonstrated a signiﬁcant agreement of AMH values ob-
served between the manual AMH Gen II assay and the Access AMH
assay on both Access 2 and DxI 800 systems with maximum difference
of 11%. In support of our results, Pearson et al. and van Helden and
Welskirchen showed high correlations between the automated Access
AMH assay and AMH Gen II assay [17,18]. Nelson et al. also reported
good linear relationship between the two AMH assays, but larger dis-
crepancy (approximately 22%) between the average AMH results [19].
Furthermore, a similar type of discordance has been demonstrated
between the AMH Gen II ELISA and the automated Elecsys AMH assay
values [19,28]. A large between-laboratory variation has already been
shown for the manual AMH Gen II assay despite good within-
laboratory performance [30]. The Access AMH assay was harmonized
with the AMH Gen II ELISA (Beckman Coulter Inc.) revised version en-
suring that any complement interference issue is prevented. The Elecsys
AMH assay was standardized against the AMH Gen II assay via sample
value transfer of AMH concentrations obtained using the unmodiﬁed
AMH Gen II ELISA assay [27]. Interestingly, a high degree of accordance
and correlation between the automated Elecsys AMH assay and the Ac-
cess AMH assay has been demonstrated by both authors Nelson et al.
and van Helden and Welskirchen [17,19]. These reports presumed
that the conﬂicting results on the discordance between the values ob-
tained by AMH Gen II ELISA and the automated AMH assays would
more likely be due to a high degree of between-laboratory variability
of the manual assay than to residual complement activity interference
as discussed by Gassner and Jung [19,27,28]. The lack of internationally
accepted standardization of AMH has been documented as a contribut-
ing factor to discrepancies between AMH assays [15,19]. Currently,
there is no universal AMH calibration standard. There is an urgent
need for development of a universal AMH standard to collectivelyage samples.
l 95% reference interval
pmol/L
(95% CI)
3 and 11.99–19.92) 5.20–114.60 (2.54–10.21 and 85.61–142.21)
2 and 9.49–16.97) 6.82–95.22 (5.13–9.39 and 67.73–121.19)
and 5.96–8.72) 1.22–52.66 (0.59–2.44 and 42.55–62.24)
and 5.65–8.93) 0.53–52.48 (0.11–1.96 and 40.36–63.78)
and 5.45–8.77) 0.20–51.03 (0.03–0.82 and 38.88–62.63)
and 2.11–4.31) 0.00–23.35 (0.00–0.01 and 15.08–30.76)
and 0.72–1.53) 0.00–8.19 (0.00–0.00 and 5.11–10.91)
d 113.35–171.19) 35.37–1031.59 (NA⁎ and 809.31–1222.31)
d 93.20–183.17) 35.87–1000.03 (NA⁎ and 665.47–1307.83)
2 and 29.74–115.28) 18.63–541.92 (15.58–23.68 and 212.38–823.08)
.53 and 14.64–26.04) 3.04–143.82 (0.10–18.05 and 104.51–185.96)
6 and 13.57–28.18) 13.90–151.38 (8.37–23.25 and 96.87–201.18)
–20.71 and 189.28–331.06) 107.92–1903.49 (81.52–147.85 and 1351.43–2363.77)
and 1.73–4.95) 0.04–24.19 (0.01–0.14 and 12.34–35.31)
Fig. 3. Lot-to-lot comparability on four lots of assay controls (two levels per lot) and two lot of patient samples (three levels per lot) run on nine different reagent pack lots using twelve
different calibrator lots over a year of testing. One red dot represents one replicate of one control level run per pack lot and one blue dot is one replicate of one patient sample level run per
pack lot.
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when different assays are used [19,31].
Reference intervals for Access AMHwere determined to address the
need for assay-speciﬁc ranges. For the ﬁrst time, this study provides
male Tanner stage AMH reference intervals established for the automat-
ed Access AMH assay. Grinspon et al. determined AMH reference levels
in normal males, from newborns to adults [4]; however, the evaluation
was conducted with the manual AMH/MIS ELISA from Beckman-
Coulter-Immunotech [32] by using a pair of antibodies different from
those used in the Access AMH assay. We determined male Tanner
stage AMH reference intervals for the Access AMH assay to address
the need for evaluation of gonadal function and cryptorchidism, and
for guidance of etiological diagnosis of pediatric male hypogonadism
[4,10].
Notably, the Access AMH assay had high lot-to-lot precision based
on the lot-to-lot comparison experiments on controls and patient sam-
ples showing a bias of b3.7% in the AMH range between 2.81 and
15.3 ng/mL for the nine assay lots using twelve calibrator lots over a
year of testing. The reduced lot-to-lot variability with the Access AMH
assay arises from the rigid lot standardization process, which involves
comparison with a panel of native samples and calibrators with target
values traceable to the AMHGen II ELISA. Lack of universal standardiza-
tion of current AMH assays to a certiﬁed referencematerial is one of the
principal unmet needs in the quantiﬁcation of AMH [17,19]. A recent
guideline – published by the National Institute for Health and Clinical
Excellence in 2013 (NICE, 2013) – stated speciﬁc AMH cut-off values
to predict ovarian response to stimulation and guide treatment deci-
sions [33]. Universal cut-off concentrations should only be recommend-
ed, however, when the results from AMH assays between lot, between
laboratory, and over time are highly reproducible. The Access AMH
assay, with an excellent lot-to-lot precision, fulﬁlls all these criteria.
The Access AMH assay demonstrated excellent performance
characteristics and exhibited good concordance with the AMH Gen II
ELISA, recognized as the current clinical standard assay. In addition to
the design of the assay, the excellent performance can also be attributed
to the fully automated procedure on the Access system. The automated
Access AMH assay is helpful in the investigation of women's fertility
problems and management of reproductive health, and offers perspec-
tives for wider acceptance of AMH testing into routine clinical practice.
Additionally, this newAMHassay provided a high lot-to-lot comparabil-
ity. In conclusion, the Access AMH assay demonstrates that results canbe replicated to a high degree across laboratories and manufactured
reagent lots. This represents a fundamental prerequisite for the estab-
lishment of a robust cut-off value for the future and for use as a new
clinical reference assay pending availability of an international AMH
standard.
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